Background
Medulloblastoma is the most common malignant brain tumor of childhood. Current therapy consisting of surgery, irradiation of the entire brain and spine followed by cytotoxic chemotherapy results in 5 year overall survival rates of approximately 70%. However, two major challenges remain. The first is that recurrent disease is almost uniformly fatal and second, treatment of young children with radiation therapy results in devastating long term side effects.
